PARIS–(HSMN NewsFeed)–Ipsen (Paris:IPN), an innovation-driven global specialty pharma Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have …
Biopharmaceuticals, Oncology, Regulatory
Ipsen , Decapeptyl, triptorelin, prostate cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Ipsen’s Decapeptyl(R) 6-Month Formulation Receives Marketing Authorization in France for the Treatment of Locally Advanced or Metastatic Prostate Cancer”
Leave a Comment